NewsPress
12 June 2026
Alterity Therapeutics Gains National Spotlight as MSA Awareness and ATH434 Development Progress Gather Momentum
Alterity Therapeutics Gains National Spotlight as MSA Awareness and ATH434 Development Progress Gather Momentum

MST Access company under coverage, Alterity Therapeutics Chief Medical Advisor, Dr Daniel Claassen was featured on A Current Affair this week, helping bring greater awareness to Multiple System Atrophy (MSA) — a devastating and currently incurable neurodegenerative disease.

The segment highlighted Alterity Therapeutics work advancing ATH434, with the company recently achieving a significant regulatory milestone after the FDA agreed to its proposed Phase 3 trial design. Patient recruitment is expected to commence before year-end.

It's encouraging to see broader mainstream recognition of both the unmet need facing MSA patients and the important work being undertaken by Australian biotech companies such as Alterity Therapeutics.

To read our latest MST Access research note on Alterity Therapeutics: https://lnkd.in/g9pwC49a

To watch the A Current Affair feature: https://www.youtube.com/watch?v=X3S5fvzK1S4

Dan Hurren

#MSTAccess #MSTFinancial #ASX #Investing #Finance #Healthcare #Biotechnology #NeurodegenerativeDiseases #FDAApproval #Innovation #AlterityTherapeutics #MSA

https://www.linkedin.com/feed/update/urn:li:activity:7471086220085862400

Press
Copy link
Research
OverviewAnalystsStock CoverageLog in
Services
Capital MarketsAdvisorySales & TradingIncome
Products
Monthly Income FundAustralian Bond FundIndividually Managed Accounts
Resources
AboutNewsContact

All material on this website has been prepared by MST Financial Services Pty Limited (ABN 54 617 475 180, AFSL 500 557) for general informational purposes only and is not a solicitation of any offer to buy or sell any financial instrument or to participate in any trading strategy. Unless otherwise stated, the material presented on this site is not a research report as defined under ASIC guidance. For wholesale clients only. This material is only prepared for wholesale clients pursuant to section 761G(7) of the Corporations Act (Commonwealth). Please also refer to MST's Privacy Policy, Terms of Use and Financial Services Guide.

Some of the products referred to on this website are issued by Equity Trustees Limited (ABN 46 004 031 298, AFSL 240975), the Responsible Entity of the funds. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a company listed on the ASX (ASX: EQT). Before making any investment decision, you should carefully review the relevant disclosure documents, including the Product Disclosure Statement (PDS), Reference Guide (RG), and Target Market Determination (TMD), available from Equity Trustees. For MST Individually Managed Accounts (IMAs), please refer to the Information Memorandum. MST does not warrant the accuracy or completeness of the information provided and disclaims all liability for any errors or omissions, to the extent permitted by law. Past performance is not a reliable indicator of future performance.

© 2026 MST Financial | All rights reserved | Designed by Comma
Privacy PolicyTerms of UseResearch DisclosuresFinancial Services Guide